Persistently Altered Metabolic Phenotype following Perinatal Excitotoxic Brain Injury

Benjamin J Blaise1, Leslie Schwendimann, Vibol Chhor

  • 1Biomolecular Medicine, Division of Computational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.

Insights

Excitotoxicity in infant brains causes lasting damage. Metabolic profiling revealed specific amino acid and lipid changes in the brain, not plasma, offering potential biomarkers for diagnosis and therapy.

Area of Science:

  • Neuroscience
  • Metabolomics
  • Developmental Biology

Background:

  • Excitotoxicity is a significant cause of brain injury in infants, leading to long-term cognitive and social deficits.
  • Understanding excitotoxicity's acute and persistent effects is crucial for developing biomarkers and therapies for affected infants.

Purpose of the Study:

  • To investigate the metabolic changes in the neonatal mouse brain and plasma following an excitotoxic lesion.
  • To identify potential metabolic biomarkers for acute and delayed responses to neonatal brain injury.

Main Methods:

  • Neonatal mice (postnatal day 5) received an excitotoxic lesion (intracerebral ibotenate) or control (PBS) injection.
  • Mass spectrometry was used to analyze metabolic profiles of brain tissue and plasma at multiple time points (postnatal days 8, 9, 10, and 30).

Main Results:

  • No significant metabolic differences were observed in plasma between control and excitotoxic groups.
  • Brain tissue analysis revealed significant alterations in amino acids (e.g., glutamine, proline) and glycerophospholipids following the excitotoxic lesion.
  • Specific changes included increased glutamine, proline, serine, threonine, tryptophan, valine, and sphingolipid SM C26:1, and decreased phosphatidylcholine (PC aa) species.

Conclusions:

  • Metabolic profiling effectively identifies acute and delayed effects of excitotoxicity in a neonatal brain injury model.
  • Alterations in specific amino acids and glycerophospholipids represent potential targets for identifying, stratifying, and treating neonatal brain injury.